The Short-Term Efficacy of Novel No-Touch Combined Directional Perfusion Radiofrequency Ablation in the Treatment of Small Hepatocellular Carcinoma with Cirrhosis

Abstract

Background

No-touch combined directed perfusion radiofrequency ablation (NTDP-RFA) is a new technique for the treatment of hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the short-term efficacy of this new technique for the treatment of small HCC with cirrhosis.

Methods

From January 2017 to March 2018, 56 consecutive patients treated with NTDP-RFA at our center were enrolled in this retrospective study. All NTDP-RFA procedures involved the use of internally cooled wet electrodes with a directional injection function, which can perform both intraelectrode cooling and extraelectrode saline perfusion. Survival curves were analyzed using Kaplan–Meier methods, and Cox proportional hazards regression analyses were used to assess predictors of tumor progression and overall survival. Operative characteristics and complications were also assessed.

Results

No technical failure occurred, and the complete ablation rate after single NTDP-RFA treatment was 98.2%. The median tumor diameter and ablation time were 26 (18.0 − 28.0) mm and 8 (6 – 8) min, respectively. Mild complications occurred in five patients (8.9%) postoperatively, and the median hospital stay was 4 (4 − 5) days. In the 18 patients (32.1%) with poor liver function reserve (indocyanine green retention rate at 15 min > 15%, their liver function returned to normal on the third day after the postoperation. The 1- and 2-year local and distant progression rates were 1.7%, 7.1%, 3.5% and 10.7%, respectively.

Conclusions

NTDP-RFA in the treatment of small HCC with cirrhosis has a low incidence of complications and provides a high survival rate without local tumor progression.

Keywords:

• radiofrequency ablation
• no-touch
• directional perfusion
• saline-enhanced electrodes
• hepatocellular carcinoma

This article is referred to by:

Clinical Utility of Advances in Radiofrequency Ablation for Small Hepatocellular Carcinoma

Acknowledgements

The authors thank all the medical staff at the Clinical Research Center of Southwest Hospital.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This work was funded by National Natural Science Foundation of China [number 81672857, number 82073346], The Chongqing Technology Innovation and Application Development Project [number cstc2019jscx-msxmX0230], Clinical Research Fund of the Army Medical University [number SWH2017ZDCX4101].